Skip to content
BioCentury This Week cover art

All episodes

BioCentury This Week, 407 episodes. Page 1 of 5.

#
Title
1

Ep. 397 - What the U.S. midterms mean for biopharma

2

Ep. 396 - China’s first-order innovation

3

Ep. 395 - ESMO analysis & Auchincloss proposal

4

Ep. 394 - Security concerns in U.S., China reshaping biotech

E
5

Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau

6

Ep. 392 - Biotech markets: Pause before the storm?

7

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

8

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

9

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

10

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

11

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

12

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

13

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

14

Ep. 384 - Back to School Special: The global FIH trials race

15

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

16

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

17

Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs

18

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

19

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

20

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

21

Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

22

Ep. 376 - M&A momentum: 3Q public markets preview

23

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

24

Ep. 374 - Parkinson's deep dive & FDA trial reforms

25

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

26

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

27

Ep. 371 - Moving faster at the academia-industry interface

28

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

29

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

30

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

31

Ep. 367 - FDA, obesity targets and the rise of DACs

32

Ep. 366 - Europe's need for speed: Bio€quity takeaways

33

Ep. 365 - Thin ice for Makary, redosing AAVs

34

Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

35

Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

36

Ep. 362 - AACR: Data and de-risking

37

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

38

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

39

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

40

Ep. 358 - Europe's biotech challenge

41

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

42

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

43

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

44

Ep. 354 - East-West Summit Takeaways

45

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

46

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

47

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

48

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

49

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

50

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

51

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

52

Ep. 346 - 2026 Public Markets Preview

53

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

54

Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

55

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

56

Ep. 342 - 2026 Biotech Kickoff

57

Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

58

Ep. 340 - Obesity Data, Kymera & FDA Survey Results

59

Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

60

Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding

61

Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc

62

Ep. 336 - Cautious Optimism and M&A Momentum

63

Ep. 335 - Neurology's Coming Inflection Point

64

Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi

65

Ep. 333 - Is This Korea’s Biotech Moment?

66

Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA

67

Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster

68

Ep. 330 - China's Innovation Moment

69

Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors

70

Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers

71

Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg

72

Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A

73

Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund

74

Ep. 324 - Genmab, GSK and Drug Pricing

75

Ep. 323 - Agentic AI: From New Targets to the Clinic

76

Ep. 322 - Takeaways from BioCentury Grand Rounds Europe

77

Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus

78

Ep. 320 - U.K. Biotech, U.S.-China, Insmed

79

Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more

80

Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines

81

Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat

82

Ep. 316 - Trends in Pharma Deals

83

Ep. 315 - China Speed: Data, Deals, First in Class

84

Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure

85

Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer

86

Ep. 312 - Biotech Progress Report

87

Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More

88

Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER

89

Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days

90

Ep. 308 - Grand Rounds - Europe Preview

91

Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA

92

Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences

93

Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2

94

Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future

95

Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future

96

Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago

97

Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans

98

Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat

99

Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs

100

Ep. 298 - Takeaways from the 25th Bio€quity Europe